Advances in the diagnosis and treatment of viral hepatitis B and C in China

[16] The proportion of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in the prescribed antiviral agents had increased from 13.5% in 2003 to 79.7% in 2016 as shown by an analysis of the China Registry of Hepatitis B.[18] In 2019, the price of generic ETV and TDF has reduced by 90%, and the...

Full description

Saved in:
Bibliographic Details
Published inChinese medical journal Vol. 135; no. 4; pp. 379 - 380
Main Author Jia, Jidong
Format Journal Article
LanguageEnglish
Published China Lippincott Williams & Wilkins 20.02.2022
Lippincott Williams & Wilkins Ovid Technologies
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
Wolters Kluwer
Subjects
Antiretroviral drugs
Antiviral drugs
China
Disease prevention
DNA, Viral
Hepatitis B
Hepatitis B - diagnosis
Hepatitis B - drug therapy
Hepatitis B virus
Hepatitis C
Hepatitis, Viral, Human - diagnosis
Hepatology
Humans
Immunization
Infections
Infectious diseases
Liver
Medical diagnosis
Medical treatment
Public health
China
Beijing China
Online AccessGet full text

Cover

More Information
Summary:[16] The proportion of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in the prescribed antiviral agents had increased from 13.5% in 2003 to 79.7% in 2016 as shown by an analysis of the China Registry of Hepatitis B.[18] In 2019, the price of generic ETV and TDF has reduced by 90%, and the price of propriety ETV, TDF, and tenofovir alafenamide fumarate has also dramatically reduced. After massive price reduction through governmental negotiation, all of these highly efficacious DAAs have been included in the reimbursement list of the basic social health insurance. According to estimates, in China, only around 25% of all HBV and 30% of all HCV cases were actually diagnosed, and 17% of CHB and 9% of CHC patients eligible for treatment were actually treated. [2] Studies suggested that scaling up of the test-and-treat strategy could dramatically reduce HBV- or HCV-associated mortality, which is cost-effective or even cost-saving. [...]continuous efforts to improve the awareness of HBV and HCV and resource allocation on their prevention, test, and treatment are still needed to eliminate viral hepatitis as a public health threat by 2030.
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0366-6999
2542-5641
2542-5641
DOI:10.1097/CM9.0000000000001886